A two arm, randomized, multicentric, open label, efficacy and safety study of Docetaxel Lipid Suspension (DLS) for Injection of Intas Pharmaceuticals Limited, India in Non-Small Cell Lung Cancer patients. - NA
Latest Information Update: 27 Oct 2022
At a glance
- Drugs Docetaxel (Primary)
- Indications Non-small cell lung cancer
- Focus Therapeutic Use
- Sponsors Intas Pharmaceuticals
Most Recent Events
- 13 Sep 2022 Status changed from recruiting to completed as per results presented at the 47th European Society for Medical Oncology Congress
- 13 Sep 2022 Results presented at the 47th European Society for Medical Oncology Congress
- 30 Apr 2018 Status changed from not yet recruiting to recruiting.